Kristine Rawlings, PharmD

Articles

Drugs in Perspective: Lemtrada (alemtuzumab)

March 17, 2015

Lemtrada (alemtuzumab) received FDA approval on November 14, 2014, under fast track designation, for the treatment of patients with relapsing forms of MS.Due to the safety profile, alemtuzumab should generally be reserved for patients who have had an inadequate response to 2 or more drugs indicated for MS.